Navigation Links
Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
Date:12/2/2009

age was 600 mg/day), and is more common in the elderly.

Severe congestive heart failure and left ventricular dysfunction have occasionally been reported. Most of the patients with reported cardiac events have had other comorbidities and risk factors, including advanced age and previous medical history of cardiac disease. Patients with cardiac disease or risk factors for cardiac failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac failure should be evaluated and treated.

Hepatotoxicity, occasionally severe, may occur. Assess liver function before initiation of treatment and monthly thereafter or as clinically indicated. Monitor liver function when combined with chemotherapy known to be associated with liver dysfunction. A 25% decrease in the recommended dose should be used for patients with severe hepatic impairment.

Patients with moderate renal impairment (CrCL = 20-39 mL/min) should receive a 50% decrease in the recommended starting dose, and future doses can be increased as tolerated. Doses greater than 600 mg/day are not recommended in patients with mild renal impairment (CrCL = 40-59 mL/min). For patients with moderate renal impairment, doses greater than 400 mg/day are not recommended. Gleevec should be used with caution in patients with severe renal impairment.

In the newly diagnosed CML trial, 2% of patients had (NCI Grades 3/4) hemorrhage.

There have also been reports, including fatalities, of cardiac tamponade, cerebral edema, acute respiratory failure, and gastrointestinal (GI) perforation.

Bullous dermatologic reactions (eg, erythema multiforme and Stevens-Johnson syndrome) have also been reported. In some cases, the reaction recurred upon rechallenge. Several postmarketing reports describe patients able to tolerate the reintroduction of Gleevec at a lower dose with or without concomitant corticosteroids or antihistamines following resol
'/>"/>

SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
10. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  Medimetriks Pharmaceuticals, Inc. announced today that ... clinical study for Ozenoxacin, a novel bactericidal non-fluorinated ... exclusive U.S. rights to Ozenoxacin 1% cream.  ... centers with an emphasis on U.S. patients, involved ... and older with a clinical diagnosis of bullous ...
(Date:7/30/2015)... VIEJO, Calif. , July 30, 2015 /PRNewswire/ ... aspiring to eliminate all preventable hospitalization, recently received ... that its Remote Patient Intelligence (RPI) solution meets ... the FDA intends to exercise "Enforcement Discretion." ... "are not subject to further FDA regulatory requirements ...
(Date:7/30/2015)... /PRNewswire/ - Anything Technologies Media, Inc. (OTC:EXMT) has announced ... Solutions (FIGS), www.frontiergarden.com has been announced ... Manager for a My Compassion originated medical cannabis ... in Alaska.  The project will be funded through ... Partners. The first phase of the project, is ...
Breaking Medicine Technology:Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 2FDA Clears Way for Commercial Marketing of Sentrian Remote Patient Intelligence Solution 3Frontier Indoor Garden Solutions announced as Horticultural Supplier and Project Manager for Alaskan Tribal Medical Marijuana Grow Facility 2Frontier Indoor Garden Solutions announced as Horticultural Supplier and Project Manager for Alaskan Tribal Medical Marijuana Grow Facility 3
... April 25, 2007-Labtec GmbH (Langenfeld,Germany), a specialty ... dose clinical study for their proprietary,Sufentanil transdermal ... announce the successful,completion of the second clinical ... this program was to complete this study ...
... 2007 - Columbia,Laboratories, Inc. (NASDAQ: CBRX) today ... analysis of the recently-completed,randomized, placebo-controlled, double-blind Phase ... for the prevention of,preterm birth in women ... weeks gestation has revealed a possible effect ...
Cached Medicine Technology:Labtec’s Next Generation Pain Patch Successful in Clinical,Studies 2Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth 2Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth 3
(Date:7/31/2015)... ... 2015 , ... “ Crack’em ” was featured on NewsWatch as part of ... consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the review ... , Cooking can be a very messy experience, especially when cracking eggs. Cracking an ...
(Date:7/31/2015)... ... July 31, 2015 , ... Nutritional Products International, ... nutritional and wellness products, announced the addition of Vincent Aquilino to its Board ... isolated stretching and the prevention and rehabilitation of injuries, has spent the last ...
(Date:7/31/2015)... ... July 31, 2015 , ... Intellitec Solutions ... recent implementation of Microsoft Dynamics GP for a senior living facility in Maine. ... supporting senior living communities in 16 states. This further expansion was again a ...
(Date:7/31/2015)... ... July 31, 2015 , ... With the ... number of individuals who remain undiagnosed, treatment options for patients are becoming more ... traditional CPAP therapy due to its overall lack of comfort and highly invasive ...
(Date:7/30/2015)... ... July 31, 2015 , ... Reduce Human Error on the ... FDAnews and Ginette M. Collazo, Inc.**, Sept. 16-17, 2015 – Raleigh, NC, ... biologic and device firms reduce manufacturing errors by 50 percent or more, will ...
Breaking Medicine News(10 mins):Health News:Make Less Mess while Cooking with Crack’em 2Health News:NPI Welcomes Vincent Aquilino to Board of Directors 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Oravan Sleep Apnea Device Gains Traction in Sleep Industry 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4
... be entangled in a health controversy now in China. Scientists ... causing agent, in potato fries exceeds the limit in drinking ... times.// ,The Chinese Ministry of Health said that measures ... acrylamide in humans. ,In April, the Chinese Ministry of ...
... reduce men's deaths from heart disease - even when ... above finding holds good regardless of the cholesterol level ... risk of dying from cardiovascular disease if they are ... effect relationship with respect to cardiovascular disease discovered that ...
... have published the results of their work linking mutations in ... was published in the Journal of Medical Ethics. //Mutations in ... and ovarian cancer in women has now found to increase ... men. The results of the study also confirmed the relation ...
... women confirms previous studies showing that a high-protein diet ... high carbohydrate diet. Researchers have also demonstrated that when ... protein-rich diet is still more effective at reducing body ... interactive effect when a protein-rich diet is combined with ...
... obesity is severe like never before. The problem seems to ... from Tufts University this month proves, when it comes to ... ,''It's quite astounding -- this shows that we can't afford ... specialist involved with the initiative that brought the girls to ...
... had discovered that a single molecule is responsible for ... body. // ,By blocking the molecule’s anchoring ... to stave off the most common serious infection of ... childhood death and disability. The researchers’ findings appear in ...
Cached Medicine News:Health News:French Fries In Cancer Controversy In China 2Health News:A Protein-Rich Diet Combined With Exercise Found To Be More Effective In Weight Loss 2Health News:Early Awareness About Weight Management Needed To Tackle Lifelong Obesity 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: